3.4399

8.81% 0.3199

Abcellera Biologics Inc (ABCL)

Overview News Price History Option Chain Financials Why ABCL Down? Discussions Forecast

Abcellera Biologics Inc stock is traded at $3.4399, with a volume of 5.73M. It is up +8.81% in the last 24 hours and up +67.24% over the past month. AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Previous Close:

$3.12

Open:

$3.15

24h Volume:

5.73M

Relative Volume:

1.23

Market Cap:

$901.42M

Revenue:

$38.03M

Net Income/Loss:

$-146.40M

P/E Ratio:

-6.6152

EPS:

-0.52

Net Cash Flow:

$-121.38M

1W Performance:

+5.11%

1M Performance:

+67.24%

6M Performance:

+26.21%

1Y Performance:

+12.42%

1-Day Range:

$3.10

$3.50

1-Week Range:

$2.98

$3.50

52-Week Range:

$1.8906

$3.68

Abcellera Biologics Inc Stock (ABCL) Company Profile

Name

Abcellera Biologics Inc

Sector

Healthcare (1173)

Industry

Biotechnology (662)

Phone

(604) 559-9005

Address

150 W 4TH AVENUE, VANCOUVER

Employee

596

Twitter

Next Earnings Date

2024-11-18

Latest SEC Filings

ABCL's Discussions on Twitter

Compare ABCL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABCL Abcellera Biologics Inc	3.42	901.42M	38.03M	-146.40M	-121.38M	-0.52
VRTX Vertex Pharmaceuticals Inc	447.63	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	514.81	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	313.57	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	543.58	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	254.18	28.51B	3.81B	-644.79M	-669.77M	-6.24

Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-20-24	Downgrade	The Benchmark Company	Buy → Hold
Feb-22-24	Upgrade	The Benchmark Company	Hold → Buy
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight
Nov-06-23	Downgrade	The Benchmark Company	Buy → Hold
Oct-13-23	Resumed	Piper Sandler	Overweight
Feb-28-23	Initiated	Cowen	Outperform
Dec-15-22	Initiated	Goldman	Buy
Nov-16-22	Initiated	Truist	Buy
Dec-21-21	Initiated	The Benchmark Company	Buy
Nov-19-21	Initiated	Piper Sandler	Overweight
Jan-05-21	Initiated	BMO Capital Markets	Outperform
Jan-05-21	Initiated	Berenberg	Buy
Jan-05-21	Initiated	Credit Suisse	Outperform
Jan-05-21	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	Stifel	Buy

View All

Abcellera Biologics Inc Stock (ABCL) Latest News

Jun 13, 2025

AbCellera shareholders approve board election and auditor - Investing.com Australia

Jun 13, 2025

AbCellera shareholders approve board election and auditor By Investing.com - Investing.com Nigeria

Jun 13, 2025

AbCellera Biologics Holds Annual Shareholder Meeting - TipRanks

Jun 13, 2025

AbCellera Biologics: The Dilemma Of A Promising Pipeline Alongside Cash Burn (ABCL) - Seeking Alpha

Jun 13, 2025

Jun 12, 2025

ABCELLERA BIOLG (ABCL) Upgraded to Buy: Here's Why - MSN

Jun 12, 2025

Jun 11, 2025

AbCellera Biologics (ABCL) Stands Out in Active Option Classes | - GuruFocus

Jun 11, 2025

AbCellera Biologics (ABCL) Stands Out in Active Option Classes | ABCL Stock News - GuruFocus

Jun 11, 2025

Jun 09, 2025